Generic Medicine Info
Indications and Dosage
Parkinson's disease
Adult: Initially, 0.1 mg at bedtime, additional doses of 0.1 mg at wkly intervals may be given, 1st in the morning then at midday. Further increases of 0.1 mg wkly may be made until an optimum response is obtained, using the same sequence of increases, starting w/ the bedtime dose. Max: 2 mg daily in 3 or 4 divided doses.

Suppression of lactation
Adult: 0.2 mg bid to tid for 14 days starting w/in the 1st 24 hr of delivery or abortion.

Acromegaly, Hyperprolactinaemia-associated disorders
Adult: 0.1 mg in the evening of the 1st day, followed by 0.1 mg at midday and in the evening of the 2nd day, then 0.1 mg in the morning, at midday and in the evening of the 3rd day. Treatment is continued and adjusted according to prolactin levels (hyperprolactinaemia) or growth hormone levels (acromegaly).
Should be taken with food. Always take w/ a meal or snack.
Serious peripheral arterial disorders and coronary insufficiency. Concomitant use w/ phenylpropanolamine.
Special Precautions
Patient w/ past or present psychosis. Avoid abrupt withdrawal. Pregnancy and lactation.
Adverse Reactions
Nausea, vomiting, dry mouth, obstipation, peripheral oedema, sweating, hallucination, anxiety, confusion, nightmares, insomnia, decreased appetite, dyskinesia, somnolence, vertigo, headache, dystonia, myoclonus, orthostatic hypotension, cold extremities, erythromelalgia, palpitation, dyspnoea.
Patient Counseling Information
This drug may cause somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor regularly for development of impulse control disorders.
Symptoms: Severe dopamine-agonistic reactions e.g. nausea, vomiting and vertigo. Management: Metoclopramide oral drops (or domperidone in parkinsonism) may be given as antidote for mild cases. Severe cases may be treated w/ IM sulpiride 100 mg.
Drug Interactions
Enhanced sedative effect w/ drugs that have CNS depressant effects (e.g. benzodiazepines, antipsychotics). Mutual antagonistic effect w/ antipsychotic neuroleptics (except clozapine). Risk of vasoconstriction and/or hypertensive crisis w/ sympathomimetics (alpha and indirect) and vasoconstrictive ergot alkaloids. Increased risk of neuropsychic disorders w/ anticholinergic antiparkinsonians. Effects may be attenuated by neuroleptics and other dopamine antagonists.
Potentially Fatal: Risk of vasoconstriction and/or hypertensive crises w/ phenylpropanolamine.
Food Interaction
Enhanced sedative effect w/ alcohol.
Mechanism of Action: Lisuride directly stimulates postsynaptic dopamine receptors, thereby improving or eliminating the reduced locomotion, rigor and tremor. It also suppresses the normal production and flow of milk and improves pathological states of the mammary gland.
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.1-1.3 hr.
Distribution: Widely distributed into the body. Volume of distribution: 2.3 L/kg. Plasma protein binding: 66%.
Metabolism: Undergoes hepatic metabolism, mainly via oxidation pathways including N'-desalkylation of ethyl groups, hydroxylation of the benzene ring, mono-oxygenation and oxidation of double bonds.
Excretion: Via urine, as metabolites. Plasma elimination half-life: 10 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Lisuride, CID=28864, (accessed on Jan. 22, 2020)

Store below 30°C. Protect from light.
MIMS Class
Antiparkinsonian Drugs / Other Drugs Affecting Hormonal Regulation
ATC Classification
N02CA07 - lisuride ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
G02CB02 - lisuride ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
Bayer New Zealand Limited. Dopergin Tablet data sheet 11 April 2013. Medsafe. Accessed 07/04/2016.

Buckingham R (ed). Lisuride Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/04/2016.

Disclaimer: This information is independently developed by MIMS based on Lisuride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in